Table 4 Subgroup analysis of the included studies for outcome oligodendrocytes cell counts.

From: Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis

Subgroup

Comparisons

Effect estimate [95% CI]

I2

Overall

55

2.09 [1.52, 2.66]

87%

Therapeutic regimen

therapeutically

49

2.10 [1.48, 2.71]

86%

Method

APC*

20

2.43 [1.48, 3.38]

88%

GST-pi

11

2.14 [0.91, 3.37]

83%

Nogo-A*

9

0.12 [−1.16, 1.36]

72%

CA2

5

3.64 [1.71, 5. 57]

83%

O4

3

4.86 [2.31, 7.41]

96%

Olig2/APC

3

2.51 [0.13, 4.89]

48%

MS model

Cuprizone***

42

1.77 [1.12, 2.41]

86%

Lysolecithin***

10

3.71 [2.27, 5.15]

91%

  1. The effect estimate was displayed by the standardized mean difference (SMD) and 95% confidence intervals (CIs). *Significant subgroup analysis between Nogo-A and APC (adjusted p = 0.049), and Cuprizone and Lysolecithin.
Back to article page